The University of Houston in partnership with Humana is now offering a six-course, fully online program focusing on value-based care. Photo via UH.edu

Last week, the University of Houston announced a new online program that will provide specialized value-based care training for providers, academia and other business and industry professionals.

UH teamed up with Kentucky-based health insurance giant, Humana, to create the new Value-based Care Specialization program that will teach the fundamentals and real-world application of value-based care. The flexible, fully-online program is being provided via the collaborative Humana Integrated Health System Sciences Institute and through global online learning platform Coursera.

"This readily available and affordable option will support those who are working with practices and providers to create better outcomes for their patients," says Tray Cockerell, director of strategy advancement for Humana, in a news release. "It's more important than ever, with the tumult caused by COVID-19, that practices focus on prevention and care coordination.

"We learned in 2020 that providers in value-based care agreements were better positioned to withstand the financial impact the pandemic brought on the health care industry because they had established patient-centered medical practices.," he continues. "Because they could quickly pivot their resources into action to best serve patients, their income was not as drastically affected as those of their fee-for-service peers."

Recent surveys have shown that there is a varied understanding of the definition of value-based care within the health care industry, and now more than ever there is a need to retool the workforce.

"It's essential that those who work to improve the health of their communities speak the same language," says Dr. LeChauncy Woodard, general internist and founding director, Humana Integrated Health System Sciences Institute at the University of Houston, in the release. "The collaboration on this content assures that everyone, from the physician and nurse, to social workers, pharmacists and claims representatives, as well as consumers of health care understand what it takes to work together. These multisector partnerships help to ensure patients are receiving the best possible care and achieving the best outcomes at the lowest possible cost."

The program consists of six courses and a capstone project, and each course features a few learning modules and a summative assignment. Participants can take any of the six courses independently — receiving a certificate for each — or collectively for the specialization designation, per the release.

"The health care industry is rapidly changing, and high-quality, flexible learning can help support medical professionals preparing for the future," says Betty Vandenbosch, chief content officer at Coursera, in the release. "We are excited to partner with leaders such as the University of Houston and Humana to offer job-relevant content in the emerging area of value-based care."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.